NCT01351103 - A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Biotech Hunter

Enrollment

185

Participants

Timeline

Start Date

December 1, 2011

Primary Completion Date

June 1, 2021

Study Completion Date

June 17, 2024

Conditions

Pancreatic CancerBRAF Mutant Colorectal CancerMelanomaTriple Negative Breast CancerHead and Neck Squamous Cell CancerCervical Squamous Cell CancerEsophageal Squamous Cell CancerLung Squamous Cell Cancer

Interventions

DRUG

LGK974

BIOLOGICAL

PDR001

Trial Locations (20)

20133

Novartis Investigative Site, Milan

28009

Novartis Investigative Site, Madrid

28040

Novartis Investigative Site, Madrid

28050

Novartis Investigative Site, Madrid

45147

Novartis Investigative Site, Essen

46010

Novartis Investigative Site, Valencia

48201

Karmanos Cancer Institute Wayne St, Detroit

80131

Novartis Investigative Site, Napoli

90024

UCLA School of Medicine, Los Angeles

94800

Novartis Investigative Site, Villejuif

21287-0013

Sidney Kimmel Comprehensive Cancer Center Johns Hopkins, Baltimore

02215

Dana Farber Cancer Institute SC-7, Boston

48109-0944

University of Michigan Comprehensive Cancer Center Onc Dept., Ann Arbor

77030-4009

University of Texas/MD Anderson Cancer Center MD Anderson 2, Houston

H2W 1T8

Novartis Investigative Site, Montreal

3015 GD

Novartis Investigative Site, Rotterdam

3584CX

Novartis Investigative Site, Utrecht

08035

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat